Correlation Profile of Suppression of Tumorigenicity 2 and/or Interleukin-33 with Biomarkers in the Adipose Tissue of Individuals with Different Metabolic States
Amal Hasan,Shihab Kochumon,Ebaa Al-Ozairi,Jaakko Tuomilehto,Fahd Al-Mulla,Rasheed Ahmad
DOI: https://doi.org/10.2147/DMSO.S251978
2020-10-21
Abstract:Amal Hasan, 1 Shihab Kochumon, 1 Ebaa Al-Ozairi, 2, 3 Jaakko Tuomilehto, 4– 6 Fahd Al-Mulla, 7 Rasheed Ahmad 1 1 Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait; 2 Clinical Research Unit, Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 3 Department of Medicine, Faculty of Medicine, Kuwait City, Kuwait; 4 Research Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 5 Department of Public Health, University of Helsinki, Helsinki, Finland; 6 National School of Public Health, Madrid, Spain; 7 Department of Genetics and Bioinformatics, Functional Genomics, Dasman Diabetes Institute, Kuwait City, Kuwait Correspondence: Amal Hasan Email amal.hasan@dasmaninstitute.org Purpose: The suppression of tumorigenicity 2 (ST2) has two main splice variants including a membrane bound (ST2) form, which activates the myeloid differentiation primary response 88 (MyD88)/nuclear factor-kappa B (NF-κB) signaling pathway, and a secreted soluble form (sST2), which acts as a decoy receptor for ST2 ligand, interleukin (IL)-33. The IL-33/ST2 axis is protective against obesity, insulin resistance, and type 2 diabetes (T2D). In humans, adipose tissue IL-33 displays distinct correlation profiles with glycated hemoglobin, ST2, and other immunometabolic mediators, depending on the glycemic health of the individuals. We determined whether adipose tissue ST2 displays distinct correlation profiles with immunometabolic mediators and whether ST2 and/or IL-33 are correlated with intracellular signaling molecules. Patients and Methods: A total of 91 adults with normal glycemia, prediabetes, and T2D were included. After measuring their anthropometric and biochemical parameters, subcutaneous adipose tissues were isolated and mRNA expression of biomarkers was measured. Results: In individuals with normal glycemia, adipose tissue ST2 was directly correlated with chemokine (C-C motif) ligand (CCL)-2, CCL5, IL-12, fibrinogen-like protein 2 (FGL2) and interferon regulatory factor (IRF)-4, but inversely correlated with cytochrome C oxidase subunit 7A1. IL-33 and ST2 were directly correlated with tumor necrosis factor receptor-associated factor 6 (TRAF6), NF-κB, and nuclear factor of activated T-cells 5 (NFAT5). In individuals with prediabetes, ST2 was inversely correlated with IL-5, whereas IL-33 but not ST2 was directly correlated with MyD88 and NF-κB. In individuals with T2D, ST2 was directly correlated with CCL2, IL-1β, and IRF5. IL-33 and ST2 were directly correlated with MyD88, TRAF6, and NF-κB. Conclusion: Adipose tissue ST2 and IL-33 show different correlation profiles with various immunometabolic biomarkers depending on the metabolic state of the individuals. Therefore, targeting the IL-33/ST2 axis might form the basis for novel therapies to combat metabolic disorders. Keywords: obesity, prediabetes, type 2 diabetes, suppression of tumorigenicity 2, interleukin-33